Trial Profile
A retrospective study evaluating safety of Raltegravir in patients with HIV infected cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Dec 2016
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 02 Dec 2016 New trial record
- 12 Nov 2016 Results published in the Investigational New Drugs